Moffitt Cancer Center's M2Gen Joins ConvergeHealth in Personalized Cancer Partnership | GenomeWeb

NEW YORK (GenomeWeb News) – Moffitt Cancer Center's subsidiary M2Gen has joined Deloitte's ConvergeHealth in a partnership aimed at using analytics and Moffitt's biomarker data to develop personalized cancer treatments, Deloitte said today.

M2Gen, ConvergeHealth, and Deloitte will work together in a consortium launched by Intermountain Healthcare to contribute to biomarker discovery and genetic clinical trial matching, and to generate evidence to support personalized medicine efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.